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A B S T R A C T
CD36 and GLUT4 are the main cardiac trans-sarcolemmal transporters for long-chain fatty acids and glucose,
respectively. Together they secure the majority of cardiac energy demands. Moreover, these transporters each
represent key governing kinetic steps in cardiac fatty acid and glucose fluxes, thereby offering major sites of
regulation. The underlying mechanism of this regulation involves a perpetual vesicle-mediated trafficking (re-
cycling) of both transporters between intracellular stores (endosomes) and the cell surface. In the healthy heart,
CD36 and GLUT4 translocation to the cell surface is under short-term control of the same physiological stimuli,
most notably increased contraction and insulin secretion. However, under chronic lipid overload, a condition
that accompanies a Western lifestyle, CD36 and GLUT4 recycling are affected distinctly, with CD36 being ex-
pelled to the sarcolemma while GLUT4 is imprisoned within the endosomes. Moreover, the increased CD36
translocation towards the cell surface is a key early step, setting the heart on a route towards insulin resistance
and subsequent contractile dysfunction. Therefore, the proteins making up the trafficking machinery of CD36
need to be identified with special focus to the differences with the protein composition of the GLUT4 trafficking
machinery. These proteins that are uniquely dedicated to either CD36 or GLUT4 traffic may offer targets to
rectify aberrant substrate uptake seen in the lipid-overloaded heart. Specifically, CD36-dedicated trafficking
regulators should be inhibited, whereas such GLUT4-dedicated proteins would need to be activated. Recent
advances in the identification of CD36-dedicated trafficking proteins have disclosed the involvement of vacuolar-
type H+-ATPase and of specific vesicle-associated membrane proteins (VAMPs). In this review, we summarize
these recent findings and sketch a roadmap of CD36 and GLUT4 trafficking compatible with experimental
findings.
1. Introduction
Overconsumption of energy-rich or fatty foods predisposes to a high
risk of developing insulin resistance and eventually progresses towards
type-2 diabetes in many subjects. Cardiovascular disease, including
myocardial infarction and heart failure, is the most common cause of
death among diabetic patients. The cardiac dysfunction that develops as
a result of intramyocardial accumulation of lipid metabolites (dia-
cylglycerols and/or ceramides) follows an increasingly understood
pattern of changes including insulin resistance, decreased glucose up-
take and structural remodeling in both humans and rodent models of
lipid overfeeding [1,2]. At present it is recognized that changes in
myocellular fatty acid uptake underly the progressive lipid accumula-
tion in the heart, which then triggers further pathophysiological
changes [3].
In the healthy heart, long-chain fatty acids (hereafter referred to as
fatty acids) and glucose are the major energy substrates required to
maintain contractile function. Both substrates first are transported
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across the sarcolemma by facilitated diffusion, and then rapidly con-
verted into ‘activated metabolites’ (acyl-coenzyme A and glucose-6-
phosphate, respectively), resulting in their intracellular trapping so as
to retain a steep substrate gradient, which is the driving force for
substrate uptake. Depending on the metabolic state of the heart, fatty
acids and glucose can be stored intracellularly but only to a limited
extent, so that the bulk will be destined immediately for mitochondrial
oxidation and ATP generation to sustain contractile activity. There are
several control points in the metabolism of both substrates. For fatty
acids, entry of fatty acyl-CoA into the mitochondria via carnitine-pal-
mitoyltransferase-1 as part of the carnitine shuttle is a key regulatory
site [4]. For glucose, the regulatory sites are phosphofructokinase
(control of glycolysis) and pyruvate dehydrogenase (control of glucose
oxidation) [4]. Yet, for both substrates their transsarcolemmal uptake
has been indicated to exert most of the flux control [5,6]. For instance,
at high extracellular substrate concentration at which the uptake is
saturated, intracellular concentrations are retained at a low level, in-
dicating that saturation of uptake is not due to saturation of metabolism
[5,7]. Hence, for both substrates the cellular uptake process is a major
rate-governing step, implicating that this step is strictly regulated.
Below, we will briefly describe for both substrates how the uptake
process is regulated (Sections 1.1 and 1.2) and how this regulation is
altered during oversupply of lipids to the heart (Section 1.3) Thereafter,
we will integrate this knowledge to formulate the aims of this review in
relation to construction the roadmap of CD36 and GLUT4 trafficking
(Section 1.4).
1.1. Regulation of glucose uptake
Uptake of glucose into the heart is mediated by GLUT1 and GLUT4,
whereby GLUT1 is responsible for most of the basal uptake and GLUT4
for most of stimulus-inducible glucose uptake [8]. Concurrently, GLUT1
is mainly localized to the sarcolemma, while GLUT4 is mainly stored in
intracellular compartments such as endosomes. Exposure of cardiac
cells to appropriate stimuli then results in translocation of GLUT4 to the
sarcolemma. It needs to be stressed that the term GLUT4 translocation
reflects the net result of a change in balance between GLUT4 exocytosis
and GLUT4 endocytosis. Both processes are constantly occurring, and
most of the research supports the notion that GLUT4 endocytosis is
relatively constant and slow, whereas GLUT4 exocytosis is highly
variable: low under basal conditions and inducible by stimuli [9,10].
Moreover, exocytosis is a rapid process with changes occurring on a
time scale of minutes after the onset of stimulation, and involves ex-
cision of transport vesicles from these intracellular GLUT4 compart-
ments. On the other hand, alternative views have been described im-
plicating decreased GLUT4 endocytosis as an important regulator of
GLUT4 translocation [11]. However, for the remainder of this review
we stay away from this controversy and will use the term translocation
to indicate the net trafficking of GLUT4 to the sarcolemma. In heart, the
main physiological stimuli inducing GLUT4 translocation are hormonal
and mechanical triggers, i.e., an increase in circulating levels of insulin
and an increase in contractile activity [8,12,13]. Both stimuli activate
distinct signaling pathways to induce GLUT4 translocation, but con-
verge at the level of Rab GTPase-activating proteins (RabGAPs) via Ser/
Thr phosphorylations. The main RabGAPs involved in GLUT4 translo-
cation are AS160 and TBC1D1, which are inhibited upon Ser/Thr
phosphorylation leading to subsequent de-inhibition of Rab proteins
[14]. Rab proteins are essential drivers of vesicular trafficking of
GLUT4 via GTP/GDP cycling. Fig. 1 depicts the specific pathways for
insulin and contraction-stimulated GLUT4 translocation.
1.2. Regulation of fatty acid uptake
Myocardial uptake of fatty acids has long been considered to be
mediated by passive diffusion, but kinetic and inhibitor studies showed
that passive diffusion only contributes to a minor extent to fatty acid
uptake [15]. The bulk of fatty acid uptake is mediated by the fatty acid
transporters CD36 (officially designated SR-B2; [16]) and plasma
membrane-localized fatty acid binding protein (FABPpm), which op-
erate in a coordinated fashion [17]. FABPpm is a peripheral membrane
protein localized at the extracellular leaflet, and may scavenge fatty
acids from the extracellular medium to be transferred to CD36, which
then governs the transsarcolemmal transport, likely via facilitating flip-
flop of fatty acids across the lipid bilayer [18]. In addition, localization
of CD36 to lipid rafts and binding to caveolins may further optimize
cellular fatty acid uptake [19]. Similarly to GLUT4, a large portion of
CD36 (about half of the total pool) is stored in intracellular compart-
ments, while the remainder is present at the sarcolemma to mediate
basal uptake. Evidence from subcellular fractionation experiments and
immunohistochemistry pinpointed the (recycling) endosomes as in-
tracellular compartment for CD36 [20,21]. Hence, the subcellular CD36
localization partially overlaps with that of GLUT4 (see previous section
and Section 2.6). The similarity between CD36 and GLUT4 trafficking
even goes further. The same physiological stimuli inducing vesicle-
mediated GLUT4 translocation, i.e., insulin and contraction, also induce
vesicle-mediated CD36 translocation [6]. Still there are subtle differ-
ences in the signaling pathways needed for CD36 translocation when
compared to GLUT4 translocation (Fig. 1). Subsequently, the newly
arrived CD36 at the sarcolemma partners up with FABPpm. In contrast
to CD36, FABPpm does not recycle in the heart and is permanently
present at the sarcolemma, waiting for CD36 to arrive from its in-
tracellular location [7,18]. Upon termination of the stimuli, GLUT4 and
CD36 are re-internalized via vesicle-mediated transport to their storage
compartments, whereas FABPpm remains at the cell surface.
1.3. The heart during lipid overload
How does lipid overconsumption impact on myocellular fatty acid
uptake? As mentioned above (Section 1), the rate of myocellular fatty
acid uptake is determined by the fatty acid gradient across the sarco-
lemma, with low intracellular fatty acid concentrations maintained due
to their rapid enzymatic conversion by long-chain acyl-CoA synthetase
(ACSL) into acyl-CoA. When the fatty acid concentration in the circu-
lation rises, such as upon increased lipid consumption, the fatty acid
gradient increases because the ACSL capacity is amply sufficient to
maintain a low intracellular fatty acid concentration [6,22]. As a result,
fatty acid uptake increases, which is enabled mainly through increased
flux through CD36. In line with this, cardiomyocytes pretreated with
CD36-blocking antibodies [23] as well as hearts from CD36 knockout
mice [24,25] are protected from lipid overload in vitro and in vivo,
respectively, further demonstrating CD36 as being a key player in in-
creased fatty acid uptake in lipid overload conditions.
How does increased myocellular fatty acid uptake affect cardiac
function? The consequence of chronically increased fatty acid uptake is
an increase in fatty acid oxidation and a progressive accumulation of
fatty acid metabolites. Increased fatty acid oxidation leads to increased
levels of acetyl-CoA and of protein acetylation. On its turn, protein
acetylation inhibits insulin signaling at multiple levels as well as in-
sulin-stimulated GLUT4 translocation via unknown mechanisms [26].
The fatty acid metabolites are mostly made up of triacylglycerols stored
in lipid droplets. However, there is also an increase in intracellular
concentrations of less inert lipid metabolites such as diacylglycerols and
ceramides. These metabolites induce insulin resistance via inhibition of
insulin signaling at distinct steps [27]. Besides induction of insulin re-
sistance, the lipid accumulation leads to other lipotoxic effects, such as
lipid-induced apoptosis [28]. Ultimately, the pleiotropic actions of li-
potoxicity in the heart contribute for a significant portion of clinical
heart failure [29]. In conclusion, increased fatty acid flux via CD36 is a
key early process involved in the development of lipid-induced cardi-
omyopathy.
One important remark needs to be made regarding the mechanism
of CD36-mediated myocellular lipid accumulation. Chronical
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overexposure to lipids not only increases the entracellular-to-in-
tracellular fatty acid gradient, but also elevates the presence of CD36 at
the sarcolemma, as seen both in vitro and in vivo [22,23]. This com-
bined impact of lipid overload on the transmembrane fatty acid gra-
dient and CD36 transport capacity is part of a lipid-mediated feedfor-
ward cycle underlying excessive myocelular lipid accumulation, which
will be further detailed in Section 2.5. The increased sarcolemmal
presence of CD36 in lipid-overloaded hearts is the result of a CD36
translocation from endosomes to the sarcolemma rather than changes
in CD36 expression [22,23]. Accordingly, in hearts from rats fed a high
fat diet [22], from obese Zucker rats [30] or from diabetic db/db mice
[31], the endosomal pool of CD36 becomes depleted with a con-
comitant increase in the sarcolemmal pool. In contrast, in the lipid-
overloaded heart GLUT4 subcellular distribution shows a completely
opposite picture, i.e., with decreased sarcolemmal abundance and
concomitantly increased presence in intracellular membrane compart-
ments [6,22]. Hence, also the GLUT4 translocation machinery under-
goes alterations leading to the intracellular imprisonment of GLUT4 in
the lipid-overloaded heart. Importantly, when the time course of lipid-
induced metabolic alterations was studied in detail in palmitate-over-
exposed cardiomyocytes, the changes in CD36 traffic were already
visible within 1 h, and preceded the changes in GLUT4 traffic by>
10 h, further indicating changes in CD36 translocation as a key early
event in lipid-induced cardiomyopathy [32].
1.4. Purpose of review
Whereas the GLUT4 trafficking machinery has been the subject of
intensive investigations [33], the CD36 trafficking machinery is rela-
tively under-investigated. Our current understanding is merely that
CD36 and GLUT4 traffic share the involvement of endosomes as in-
tracellular storage compartment and the involvement of members of the
VAMP family for mediating the translocation upon different stimuli
[34]. An important feature of the endosomes is their intraluminal
acidification, which is maintained by the endosomal/lysosomal proton
pump vacuolar-type H+-ATPase (v-ATPase). Recent research revealed
that v-ATPase is a key regulator of both subcellular CD36 and GLUT4
localization [32,35]. In this review, we aim to integrate the novel lit-
erature evidence on the role of v-ATPase in the subcellular localization
of CD36 and GLUT4 together with the existing knowledge on the role of
VAMP members in their subcellular recycling. This leads us to the
drafting of a first roadmap of CD36 traffic with specific focus on the
similarities and differences with GLUT4 traffic. Such roadmap may
provide novel insights and could initiate the design of novel therapies
to redirect cardiac substrate uptake in the lipid-overloaded heart to-
wards increased glucose use. For this purpose, we will first highlight the
mechanistic role of v-ATPase in CD36 and GLUT4 traffic (Section 2),
then we present the published data on the role of VAMP members in
CD36 and GLUT4 traffic (Section 3), after which we will integrate v-
ATPase and VAMPs into a roadmap of CD36 traffic (Section 4). Finally,
based on this roadmap, we will discuss possible strategies to combat
lipid-induced cardiomyopathy (Section 5).
Fig. 1. Signaling mechanisms involved in translocation of CD36 and GLUT4 in cardiomyocytes under non-pathological conditions. The main physiological stimuli for
CD36 and GLUT4 translocation from endosomes to the cell surface are increased circulatory insulin levels and an increase in contractile activity (indicated by a
biphasic electrical pulse). Insulin binding to its receptor activates insulin receptor substrate-1 (IRS1), phosphatidylinositol-3 kinase (PI3K) and Akt2 in sequential
order, which is known as the canonical insulin signaling pathway. Contraction induces activation of AMP-activated protein kinase (AMPK) and protein kinase-D1
(PKD1) in separate pathways. Full activation of AMPK and PKD1 additionally requires phosphorylation by LKB1 and death-activated protein kinase (DAPK),
respectively. Contraction-induced CD36 translocation is mediated by AMPK activation, and contraction-induced GLUT4 translocation additionally requires PKD1
activation. For review, see [92]. Activation of Akt2 and AMPK leads to an inhibitory phosphorylation of the RabGAP proteins AS160 and TBC1D1. Please note that
the involvement of AS160 in insulin signaling and of TBC1D1 in contraction signaling is an oversimplification as both RabGAPS might also contribute to regulation of
the respective other signaling pathway. For an excellent review on this topic, see [85]. Deactivation of both RabGAPs results in liberation of the activity of several
Rabs. A number of Rabs is involved in GLUT4 translocation [12], and their involvement has also been proven in CD36 translocation [91]. Finally, upon termination of
the stimuli, both GLUT4 and CD36 return to the endosomes.
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2. v-ATPase regulates CD36 and GLUT4 traffic
Given that changes in CD36 traffic precede changes in GLUT4 traffic
upon the onset of lipid overload, we start out with discussing CD36
followed by GLUT4. The mechanism by which lipids (especially pal-
mitate) increase CD36 translocation is incompletely understood, but
recently it became evident that excess lipids interfere with one of the
hallmark properties of endosomes, i.e., maintaining intra-endosomal
acidification. More specifically, lipid-induced loss of endosomal acid-
ification was observed in vitro in cardiomyocytes cultured in high
palmitate-containing media, as well as in vivo upon feeding rats a high
fat diet [32]. Proper endosomal acidification appeared essential for
retaining CD36 within the endosomes. For instance, interfering with
endosomal acidification by treatment of cardiomyocytes with mon-
ensin, a proton ionophore, or with bafilomycin-A, an inhibitor of proton
pumping into endosomes (and other acidic vesicles), causes expulsion
of CD36 from the endosomes and subsequent translocation to the cell
surface [35]. We currently do not know why endosomal acidification is
important for CD36 retention, but it is speculated that a low endosomal
pH keeps the primary amine groups of specific phospholipids (e.g.,
phosphatidylethanolamine) in a protonated form, which favours sta-
bilization of the bilayer (because of ion pairing with negatively charged
phosphate groups of adjacent phospholipids). Such bilayer stabilization
would impair membrane curving events [36], so that budding of (CD36-
containing) transport vesicles will become more difficult.
2.1. v-ATPase pumping retains CD36 within the endosomes
Proton pumping into the lumen of endosomes and into other acidic
compartments is carried out by v-ATPase, a large multi-subunit com-
plex. This function makes v-ATPase an essential player in the regulation
of cellular compartmentalization. Structurally and functionally, the v-
ATPase complex can be divided into two sub-complexes: a membrane-
associated sub-complex (named V0) of 6 subunits forming the proton
translocation channel, and a cytoplasmic sub-complex (V1) of 8 sub-
units forming the ATP-driven rotor [37,38]. Several subunits consist in
multiple isoforms, which are expressed in a tissue-specific manner. This
implies that v-ATPase has a unique subunit isoform composition in each
tissue, giving it tissue-specific functional properties. For example, in
kidney and osteoclasts v-ATPase also co-localizes with the plasma
membrane for acid secretion and extracellular pH regulation [39]. In
the heart, less information is available on the isoform-specific expres-
sion of the v-ATPase subunits. With respect to the V0 subunit a, the a2
isoform is abundantly expressed in the heart [40], and has been asso-
ciated with an endosomal/Golgi-location [41,42]. Of note, the a4 iso-
form, which is expressed in kidney but not in heart [40,42], is asso-
ciated with a plasmalemmal localization of v-ATPase.
Given that in the heart v-ATPase is a protein resident to endosomes,
it can be inferred that CD36 colocalizes with v-ATPase, particularly
under conditions of low exogenous lipids. Accordingly, in an en-
dosomally enriched membrane fraction from cardiomyocyte lysates
from rats on a low fat diet, CD36 co-immunoprecipitates with v-ATPase
subunits a2 and B2 under non-detergent conditions, indicating that v-
ATPase and CD36 are present on the same subcellular (presumably
endosomal) vesicles [32]. In line with this, microscopical studies show
extensive co-localization of CD36 with a2 and B2 in cardiomyocytes
cultured under low palmitate conditions [43]. Additional evidence for
the involvement of v-ATPase in intracellular retention of CD36 stems
from genetic manipulation of v-ATPase via siRNA-mediated silencing of
the B2 subunit, which causes CD36 to lose its intracellular localization
and translocate to the cell surface [32].
2.2. v-ATPase regulation by assembly/disassembly
v-ATPase activity is regulated by various molecular mechanisms
including phosphorylation [37], but with respect to CD36 retention the
main mechanism of regulation involves cycles of disassembly and (re-)
assembly of the V0 and V1 sub-complexes [37,38]. V0V1 assembly/dis-
assembly is rapid and reversible, enabling a rapid modulation of v-
ATPase activity. The number of stimuli identified to alter v-ATPase
assembly status is increasing. This list includes several nutrients in-
cluding glucose [38]. Glucose re-addition upon withdrawal leads to v-
ATPase re-assembly via a mechanism whereby aldolase binds to v-AT-
Pase [44]. This aldolase binding is dependent on ongoing glycolysis, a
condition in which this enzyme is supplied with substrate, and hence in
an active mode. Interestingly, binding of another glycolytic enzyme,
phosphofructokinase, also has been reported to support v-ATPase as-
sembly [45].
2.3. Disassembly of v-ATPase by lipids
The number of metabolic signals able to regulate v-ATPase assembly
is expanding. Our current research indicates that also lipids, in parti-
cular fatty acids, are regulators of v-ATPase assembly [32]. Thus, we
observed that short-term (< 1 h) exposure of cardiomyocytes to excess
palmitate induces the disassembly of v-ATPase into its two sub-
complexes. This lipid-induced disassembly was accompanied by in-
hibition of v-ATPase activity resulting in decreased endosomal acid-
ification [32]. Hence, v-ATPase regulation by lipids is opposite to that
of glucose, so that it would be predicted that the assembly state of v-
ATPase reflects the ratio between cardiac uptake of glucose and lipids
at any given nutritional condition. Taking this a step further, the ability
of v-ATPase to sense alterations in both glucose and lipid concentra-
tions makes v-ATPase a central regulator of energy substrate metabo-
lism in heart and presumably also in any other tissue for which glucose
and lipids are key substrates.
2.4. v-ATPase disassembly and lipid-induced insulin resistance
Prolonged exposure of cardiomyocyte cultures to high palmitate
causes CD36 to be more permanently located at the sarcolemma since
the de-acidified endosomes are unable to harbor CD36 (see in-
troductory paragraph of this section). The consequently increased rate
of lipid uptake will progressively lead to intracellular accumulation of
lipid metabolites, among which ceramides and diacylglycerols, both of
which directly interfere with the canonical insulin signaling pathway
(involving IRS1, PI3K and Akt; see [27]). As a result, insulin-stimulated
GLUT4 translocation and glucose uptake as well as insulin-stimulated
CD36 translocation and fatty acid uptake are largely inhibited. The loss
of insulin-stimulated GLUT4 translocation is accompanied by a low
basal glucose uptake rate, whereas the loss of insulin-stimulated CD36
translocation does not affect the already high basal rate of lipid uptake.
Taken together, in the overt insulin resistant cardiomyocyte GLUT4 is
mainly localized intracellularly whereas CD36 is mainly present at the
cell surface. Ultimately, the combination of lipid overload and insulin
resistance will lead to loss of contractile activity of cardiomyocytes [23]
and to cardiac failure upon Western diet (Section 1.3) [27]. In con-
clusion, prolonged lipid-induced v-ATPase inhibition is a key under-
lying mechanism in lipid-induced cardiomyopathy. This is underscored
by the observation that genetic inhibition of v-ATPase (via B2 silencing,
see above) is sufficient to cause cardiomyocytic insulin resistance in the
presence of low exogenous lipid concentrations that by themselves are
insufficient to induce insulin resistance [32]. Furthermore, the v-AT-
Pase inhibition-induced insulin resistance is prevented by a pharma-
cological blockage of the lipid transport function of CD36 [32].
2.5. Feed-forward mechanism of CD36-mediated CD36 translocation
The observation that lipid-induced CD36 translocation is dependent
on entry of lipids into cardiomyocytes via CD36 already present at the
cell surface is indicative of a feed-forward cycle in myocardial lipid
uptake. Specifically, a rise in exogenous lipids (palmitate) leads to an
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increased outside-to-inside gradient and a consequently increased up-
take via CD36. These lipids enter the cell facilitated by CD36 and
subsequently cause v-ATPase disassembly, loss of endosomal acid-
ification, increased sarcolemmal CD36 presence and further increased
lipid uptake (Fig. 2). This vicious cycle of CD36-mediated CD36
translocation is expected to be the key mechanism underlying lipid-
induced cardiomyopathy. Accordingly, blocking the fatty acid-transport
function of CD36 powerfully interrupts this vicious cycle. Moreover, v-
ATPase could be a novel target in strategies to combat lipid-induced
cardiomyopathy.
2.6. v-ATPase and GLUT4
Whereas subcellular CD36 storage has been mainly confined to
endosomes [20,46], GLUT4 appears to be stored in multiple subcellular
compartments [33,47,48]. Several of these compartments overlap with
the endosomes, but there is strong evidence for the existence of a re-
latively large subcellular pool of GLUT4 outside of the endosomes. This
pool is referred to as the GLUT4 storage compartment (GSV) or as the
insulin-responsive vesicle compartment, and it contains about half of
the intracellularly stored GLUT4, at least in adipocytes (with the en-
dosomes containing the other half of subcellular GLUT4) [49]. Mor-
phologically, GSV can be distinguished from the endosomes as they are
formed from a collection of small (50–70 nm) vesicles [50], whereas the
endosomal vesicles range from 100 to 250 nm in diameter [51]. Fur-
thermore, GSV are not acidified, and lack v-ATPase. On the other hand,
GSV are equipped with a distinct subset of proteins. They contain,
among others, an insulin-regulated aminopeptidase (IRAP), which has
long been recognized to translocate in a similar manner as GLUT4 in
response to insulin [52]. More importantly, GSV contains TUG (tether
containing a UBX domain for GLUT4). TUG is responsible for GLUT4
retention within the GSV via binding to its N-terminal region [53].
Simultaneously, the C-terminal region of TUG anchors GSV to the cis-
Golgi, thereby imprisoning GLUT4. Upon insulin stimulation, TUG
undergoes an endoproteolytic cleavage [53], thereby releasing the GSV
from the Golgi and allowing these vesicles to rapidly translocate to the
cell surface. This initial GLUT4 translocation event is known as the
insulin burst [10,50]. Additionally, GLUT4 translocates from the
endosomes to the cell surface in response to insulin. However, this
process is quantitatively a minor player during the insulin burst but
gains in importance during more prolonged insulin exposure [10]. Both
the GSV and the endosomes harbor the RabGAP AS160 [54], which is
involved in the intracellular retention of GLUT4 because AS160 keeps
the Rabs in an inactive GTP-unloaded state. This intracellular retention
mechanism appears independent of that of TUG in the GSV. The iden-
tification of yet another protein involved in GLUT4 retention, desig-
nated phosphotyrosine-interacting domain-containing protein-1 (PID1)
indicates that the GSV have several different mechanisms backed up to
keep GLUT4 firmly imprisoned in the absence of stimuli [55]. Similarly
as the endosomes, the GSV may not only serve as storage compartment
for insulin-stimulated GLUT4 translocation, but also for contraction-
induced GLUT4 translocation. This novel assumption is further dis-
cussed in Section 4.2.
Studies investigating the role of endosomal acidification in GLUT4
translocation are scarce and contradictory. In adipocytes, bafilomycin-
A has been reported to inhibit [56] as well as to induce GLUT4 trans-
location [57]. The difference between both studies may be related to
the concentration of bafilomycin used, i.e., up to 50 μM in the first
study, whereas bafilomycin already completely abolishes endosomal
acidification at concentrations of< 100 nM. Results from our studies
with primary cardiomyocytes have revealed that bafilomycin treatment
leads to expulsion of GLUT4 from the endosomes [35] in agreement
with the latter study in adipocytes. Subsequently, using two in-
dependent methods (sucrose gradient centrifugation and cell surface
biotinylation), we observed that GLUT4 failed to arrive at the cell
surface [35]. Unfortunately, by using gradient centrifugation, we could
not detect the intracellular destination of GLUT4, but we assume that
GLUT4 is kicked out of the endosomes to be sent away for imprison-
ment within the GSV. The problem of detection of GSV by biochemical
methodology has been recognized as these small vesicles appear to be
easily destroyed in classical fractionation procedures [10]. Accordingly,
one could speculate that the GSV serves as the intracellular GLUT4
destination during endosomal de-acidification.
What happens to the endosomal pool of GLUT4 in the heart during
chronic lipid overload? At present, there is no direct answer to this
question. However, we must expect that this pool will undergo the same
Fig. 2. Sequence of molecular changes in-
volving CD36 and v-ATPase in lipid-induced
insulin resistance. An increase in supply of
fatty acids (palmitate) leads to CD36-medi-
ated palmitate uptake into myocytes (1).
Increased myocellular palmitate concentra-
tions are sensed by v-ATPase, resulting in
disassembly of subcomplex V1 from V0 (2)
and subsequent loss of endosomal acid-
ification (3). This endosomal dysfunction
causes expulsion of CD36, which translo-
cates to the sarcolemma (4). Simultaneously
GLUT4 is expelled from the endosomes to
migrate to the GSV (5). The increase in
surface CD36 abundance installs a feedfor-
ward cycle of increased fatty acid uptake (6)
and progressive accumulation of triacylgly-
cerol (TAG) and bioactive lipid metabolites
such as ceramides (7). Ceramides interfere
with the canonical insulin signaling
pathway at the level of Akt2 (8) resulting in
a blockade of GLUT4 translocation (9).
Eventually, in the overt insulin resistant
myocyte there is a juxtaposed localization
of CD36 and GLUT4. Luminal acidification
(of endosomes) is indicated by a blue fill
color. (For interpretation of the references
to color in this figure legend, the reader is
referred to the web version of this article.)
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fate as upon bafilomycin treatment of cells. The lipid-induced v-ATPase
disassembly and subsequent de-acidification of the endosomes [32]
therefore may lead to expulsion of both CD36 and GLUT4, after which
CD36 translocates to the cell surface and GLUT4 expectedly to the GSV,
where it will be anchored by TUG. This must be a true imprisonment for
GLUT4 because during lipid overload conditions the insulin signaling
pathway is not able to induce the endoproteolytic cleavage of TUG
needed for liberation of the GSV. Although hypothetical in nature, such
scenario may help explain why in the overt diabetic myocyte the sub-
cellular distribution of GLUT4 becomes juxtaposed to that of CD36.
However, it remains to be explained why CD36 and GLUT4 have dif-
ferent destinations after being expelled from the endosomes and which
molecules govern the transport to the default compartment for CD36
and GLUT4 when the de-acidified endosomes release these transporters.
It is not far-fetched to attribute differences in subcellular transport of
CD36 and GLUT4 to accessory proteins regulating vesicle traffic, in-
cluding VAMPs.
3. Role of VAMPs in CD36 and GLUT4 traffic
SNARE proteins play a key role in all mediated vesicular trafficking
events by enabling membrane fusion between the transport vesicle and
the target membrane. The family of SNAREs can be sub-classified into v
(esicle)-SNAREs and t(arget)-SNAREs based on their presence at the
transport vesicle or at the target membrane, respectively. The specifi-
city of pairing of v-SNARE members with cognate t-SNARE members is
a main determinant of the specificity of vesicular traffic. v-SNAREs and
t-SNAREs have complimentary motifs that bind via ‘zippering’, into a
trans-SNARE complex that overcomes the repelling forces of the two
lipid bilayers. The v-SNAREs are made up of 7 members of the VAMP
(vesicle-associated membrane protein) family while there are> 20 t-
SNAREs identified, mostly originating from the protein families of the
syntaxins and the synaptotagmins [58]. This unequal distribution im-
plies that the v-SNAREs can form specific bonds with more than one t-
SNARE, while this is not the case reciprocally. Evidence is accumulating
that phosphorylation of t- and v-SNARE proteins is involved in reg-
ulation of their function. These phosphorylations can be either stimu-
latory or inhibitory for priming of SNAREs [59]. Here, we will focus
mainly on the v-SNAREs (VAMPs) because they represent the different
intracellular compartments from which the transport vesicles are
formed. For completion, it needs to be mentioned that SNARE pairing is
essential but not sufficient for membrane fusion [60]. The latter process
also requires the participation of several adaptor proteins binding to the
SNAREs, such as synaptosome-associated proteins (SNAPs), conferring
further specificity to trafficking [61].
Since both GLUT4 translocation and CD36 translocation are medi-
ated by transport vesicles trafficking between endosomes and the cell
surface, both processes rely on SNARE proteins including VAMPs. A net
translocation of each transporter to the plasma membrane, as for any
other cargo protein, is determined by the relative rates of exocytosis
(from endosomes to the cell surface) and endocytosis (the retrograde
trafficking back to the endosomes). Because VAMPs confer specificity to
vesicular trafficking, it is to be expected that different VAMP isoforms
are involved in exocytotic pathways versus endocytotic pathways reg-
ulating the subcellular distribution of CD36 and GLUT4. Another level
of specificity relates to the stimuli, insulin and contractions, which
could utilize different VAMP isoforms to stimulate GLUT4 and CD36
translocation, as will be discussed in detail below. For GLUT4 translo-
cation, the involvement of VAMPs has been well-investigated, espe-
cially in adipocytes, whereas studies in cardiomyocytes and on the role
of VAMPs in CD36 translocation are scarce. Atrial cardiomyocytes have
been studied in relation to VAMPs because of their endocrine function
during stress, leading to secretion of atrial natriuretic peptide (ANP)
and brain natriuretic peptide (BNP). Accordingly, these cells are
equipped with almost the entire set of VAMP isoforms (only VAMP7
could not be detected at the transcript level; [58]). Furthermore, the
atrial cardiomyocyte cell line HL-1 has been used in a systematic study
of VAMPs in CD36 translocation in relation to GLUT4 via silencing each
of the resident VAMP members [34]. Ventricular cardiomyocytes also
have been shown to possess most of the VAMPs (only VAMP1 and
VAMP8 were lacking at the protein expression level; [34]). Below, we
summarize separately for each of the VAMPs the available literature
information about their roles in GLUT4 and CD36 trafficking in the
heart. We also include information, when available, on VAMPs in ske-
letal muscle and in adipocytes, in which tissues the involvements of
VAMPs has been more intensively studied. At least in skeletal muscle,
the translocation of GLUT4 and CD36 appears to be similarly regulated
[6]. For cell lines, such as HL-1 cardiomyocytes, a word of caution
seems appropriate concerning their use as model to study GLUT4 and
CD36 traffic, given that these cells are mostly glycolytic.
3.1. VAMP2
VAMP2 (also known as synaptobrevin-2) has been the first VAMP
identified to be involved in GLUT4 translocation, as found in adipo-
cytes, and has been mainly associated with insulin stimulation of
GLUT4 exocytosis [62,63]. Also in muscle, VAMP2 has been shown to
mediate insulin-stimulated GLUT4 exocytosis [64]. Data in the heart
are more limited, but VAMP2 appears to be present in the endosomes as
well as in the GSV, and upon insulin stimulation translocates simulta-
neously with GLUT4 [65]. In skeletal muscle, VAMP2 is phosphorylated
on Ser upon insulin-treatment, and there is evidence that the re-
sponsible kinase is atypical protein kinase C member PKC-ζ. Subse-
quently, this PKC-ζ-mediated VAMP2 phosphorylation may be essential
in insulin-stimulated GLUT4 translocation [66]. However in the heart,
insulin did not influence VAMP2 binding to PKC-ζ (or Akt2; [67]),
pointing towards tissue-specific differences in VAMP priming. Con-
clusive evidence that also in the heart, VAMP2 is involved in insulin-
stimulated GLUT4 translocation was derived from as siRNA-mediated
silencing of VAMP2 in HL-1 cardiomyocytes [34]. In this study, CD36
trafficking was simultaneously examined: CD36 translocation was si-
milarly stimulated by insulin as GLUT4 translocation and also blocked
by VAMP2 silencing [34]. In contrast, contraction-induced GLUT4 and
CD36 translocation were unaffected by VAMP2 silencing [34]. Re-
markably, there was also another action of VAMP2 silencing: In basal
conditions sarcolemmal CD36 levels were increased, pinpointing to a
(possible) dual role of VAMP2 in CD36 traffic, namely, the involvement
in insulin-stimulated CD36 exocytosis and in basal CD36 endocytosis
[34].
3.2. VAMP3
VAMP3 is also known as cellubrevin, and several observations in-
dicate that, just like VAMP2, it is involved in insulin-stimulated GLUT4
translocation. VAMP3 localizes to the insulin-sensitive GSV in adipo-
cytes [63], and appears to be functionally involved in GLUT4 translo-
cation [64,68]. This additional involvement of VAMP3 in insulin-sti-
mulated GLUT4 translocation next to VAMP2 suggests redundancy of
VAMPs in this process. Potent evidence for this redundancy was pro-
vided by VAMP replacement studies in adipocytes, where VAMP3 could
restore insulin-stimulated GLUT4 translocation in adipocytes with
combined ablation of VAMP2, VAMP3 and VAMP8 [69]. However,
colocalization between GLUT4 and VAMP3 was not observed in rat and
human skeletal muscle [70], and VAMP3 failed to mediate insulin-sti-
mulated GLUT4 translocation in muscle cell lines [71], pointing to-
wards a tissue-specific differences in the functioning of VAMPs in
GLUT4 translocation. Other lines of evidence excluding a role of
VAMP3 in insulin-stimulated GLUT4 translocation entailed a systematic
study on all VAMPs in GLUT4 translocation using distribution analysis
concluded that only VAMP2 is important for this process [72]. More-
over, VAMP3-knockout mice normally displayed insulin-stimulated
GLUT4 translocation [73].
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VAMP3 has also been studied in relation to exercise/contraction-
induced GLUT4 translocation, and appears not to be involved in this
process in skeletal muscle. Namely, VAMP3 does not translocate with
GLUT4 in contracting muscle [74]. Furthermore, in skeletal muscle
from VAMP3 knockout mice, contraction-induced GLUT4 translocation
is not altered [73]. In contrast, in the heart VAMP3 appears to be in-
volved in contraction-induced GLUT4 translocation and glucose uptake,
given that both processes were completely abolished in HL1-cardio-
myocytes, in which VAMP3 was knocked-down with siRNA metho-
dology [34]. In these same VAMP3-silenced cells, also contraction-in-
duced CD36 translocation was blocked [34], indicating that VAMP3 has
a broader involvement in contraction-induced subcellular trafficking.
Moreover, these combined data indicate again a tissue-specific in-
volvement of VAMP3 in GLUT4 traffic. Priming of VAMP3 upon the
onset of contraction in cardiomyocyte cultures may be due to phos-
phorylation by protein kinase-D1, a recently identified contraction-ac-
tivated kinase, which increasingly binds to VAMP3 upon contraction
[67]. In contrast, the canonical energy sensor AMPK failed to bind to
VAMP3 either in the absence or presence of contraction [67].
3.3. VAMP4
In contrast to VAMP2 and VAMP3, much less research has been
performed on the involvement of VAMP4 and the other VAMP mem-
bers. In adipocytes, VAMP4 is not directly involved in GLUT4 en-
docytosis or exocytosis, but this isoform is needed for the biosynthetic
sorting of GLUT4 from the Golgi apparatus to the recycling endosomes
[47]. Studies with siRNA-mediated silencing of VAMP4 in HL-1 cardi-
omyocytes, indicated that this isoform is also not involved in GLUT4
trafficking to and from the cell surface in response to either insulin or
contraction [34]. In contrast, in these same cardiomyocytes VAMP4
appeared to be necessary for insulin as well as contraction-induced
CD36 translocation. Therefore, the involvement of VAMP4 in CD36
traffic, but not in GLUT4 traffic renders VAMP4 as a novel target to
alter the balance between glucose and fatty acid uptake, which could be
beneficial in cardiac metabolic diseases with altered substrate pre-
ference.
3.4. VAMP5 and VAMP7
In a systematic study, in which each of the VAMP members was
silenced in adipocytes for studying their role in insulin-stimulated
GLUT4 translocation, it appeared that VAMP5 and VAMP7 were not
involved [47]. In skeletal muscle, VAMP5 and VAMP7 localize to the
intracellular GSVs and both isoforms translocate with GLUT4 to the
sarcolemma in response to electrically induced contraction [74].
However, this study unfortunately did not investigate whether both
VAMPs were necessary for contraction-induced GLUT4 translocation. In
other studies, VAMP5 and VAMP7 have been predominantly found at
the cell surface in adipocytes, skeletal muscle and heart [75–77], sug-
gesting that both VAMPs mediate endocytotic processes. VAMP5 and
VAMP7 silencing in HL1 cardiomyocytes yielded an increase in cell
surface GLUT4 under non-stimulated conditions, whereas insulin or
contraction-stimulated GLUT4 translocation were unchanged [34]. Also
basal, insulin or contraction-induced CD36 translocation was not af-
fected [34]. Although definite proof is missing, these latter findings are
compatible with specific roles of VAMP5 and VAMP7 in GLUT4 en-
docytosis in the heart. Furthermore, because of their selective in-
volvement in glucose uptake (and not in fatty acid uptake), these
VAMPs have the potential to modulate cardiac substrate preference.
3.5. VAMP8
VAMP8 (endobrevin) is distributed within the endosomal com-
partment, but more so during muscle differentiation than in mature
muscle [78]. VAMP8 has been detected by PCR in atrial cardiomyocytes
[58], but not by Western blotting in adult ventricular cardiomyocytes
[34]. In adipocytes, VAMP 8 is implicated in GLUT4 traffic, and spe-
cifically to GLUT4 endocytosis back to the recycling endosomes [47].
No observations have been described linking VAMP8 to CD36 traffic.
4. Towards a roadmap of subcellular CD36 and GLUT4 traffic by
integrating the roles of v-ATPase and VAMPs in trafficking of these
transporters
By integrating observations regarding the influence of v-ATPase and
of VAMPs on CD36 and GLUT4 translocation, we aim to create a
roadmap for subcellular trafficking of both transporters, first for CD36
(Section 4.1), then GLUT4 (Section 4.2), and finally combined (Section
4.3). The basis for this roadmap in the heart is the systematic silencing
of VAMPs in HL1 cells [34], as detailed in the previous sections
(Sections 3.1 to 3.5).
4.1. Mapping CD36 traffic
When starting to combine CD36 traffic with the involvement of
VAMPs, it immediately jumps to the attention that for CD36 translo-
cation, either stimulated by insulin or by contraction, two VAMPs are
necessary. Insulin-stimulated CD36 translocation is dependent on
VAMP2 and VAMP4, and contraction-induced CD36 translocation relies
on VAMP3 and VAMP4. Since each VAMP member is known to mediate
a specific vesicle trafficking event from a given donor compartment to a
defined acceptor compartment (see Section 3), it follows that in re-
sponse to either stimulus, CD36 does not translocate to the cell surface
in a direct manner, but makes a stopover at an intermediate station.
Hence, the first VAMP brings CD36 from the endosomal mother com-
partment to this hypothetical intermediary station; the second VAMP
brings CD36 from this station to the cell surface. What is the nature of
the intermediary station? We only can predict that it must be part of the
endosomal compartment. Namely, kinetic evidence indicates that sti-
mulus-induced CD36 translocation shares the same mechanism as CD36
translocation induced by endosomal de-acidification [35,46]. Then it
follows that if this compartment would be non-endosomal, CD36 would
be trapped here upon treatment of cells with bafilomycin or monensin,
resulting in an incomplete translocation (which does not match the
observations). It makes most sense that the VAMP involved in bringing
CD36 from the mother endosomal compartment to the intermediary
endosomal station is VAMP4. This VAMP is specifically dedicated to
CD36 traffic (and not involved in that of GLUT4). Subsequently,
VAMP2 or VAMP3 can complete the translocation of CD36 from the
intermediary station to the cell surface dependent on the type of sti-
mulus (insulin or contraction). The reciprocal scenario that upon (in-
sulin or contraction) stimulation, the VAMP responsible for the initial
CD36 translocation step is VAMP2 or VAMP3 (dependent on the sti-
mulus), can be rejected because in that situation there would be no
subcellular segregation between CD36 and GLUT4. Namely, VAMP2
and VAMP3 do not discriminate between CD36 and GLUT4 traffic. Fi-
nally, VAMP2 additionally ensures that CD36 returns to the endosomes
upon termination of the stimulation period. CD36 can then be delivered
either to the mother endosomal compartment or to the intermediary
endosomal station.
4.2. Mapping GLUT4 traffic
The systematic silencing of VAMPs in HL1 cells [34] has identified
four VAMPs to be involved in GLUT4 traffic in the heart. VAMP2 and
VAMP3 are necessary for insulin and contraction-induced translocation
of GLUT4. Given that these VAMPs fulfil similar roles in CD36 trans-
location, VAMP2 can be assigned to as ‘insulin-VAMP’, and VAMP3 as
‘contraction-VAMP’. The other VAMPs are VAMP5 and VAMP7, and
mediate the retrograde trafficking of GLUT4. The fact two VAMPs are
needed for GLUT4 internalization, is different from CD36 traffic, in
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which only one VAMP isoform was found to be operative in this respect.
A reason for this difference could be that in case of CD36 both involved
compartments (the mother compartment and the intermediary station)
are endosomal, requiring only one VAMP, whereas in case of GLUT4 the
two involved compartments are endosomal as well as non-endosomal
requiring different VAMPs. Still, we do not know which of the two
VAMPs (VAMP5 or VAMP7) specifically brings GLUT4 from the cell
surface to the GSV or which of these VAMP isoforms delivers GLUT4
back to the endosomal mother compartment.
There is another missing piece in the traffic of GLUT4. Namely, for
insulin or contraction stimulation, only one VAMP has been identified
to be involved in response to either stimulus (VAMP2 and VAMP3,
respectively, see above), while there are clearly (at least) two GLUT4
compartments, being the endosomes and the GSV. Considering a pos-
sible symmetry with CD36 traffic, the GSV could serve as the inter-
mediary station for GLUT4 traffic. Accordingly, VAMP2 or VAMP3
would mediate GLUT4 traffic from the GSV to the cell surface depen-
dent on the stimulus. However, information is lacking about the VAMP
responsible for traffic of GLUT4 from the endosomes to the GSV. There
are a few possibilities to fill this gap. First, VAMP8 that has not been
detected at the protein level in the adult heart (see Section 3.5), cannot
be entirely excluded, because it may still be possible that small amounts
of this VAMP that escaped detection by Western blotting would be re-
sponsible for this trafficking step. Interestingly, VAMP 8 is also im-
plicated in GLUT4 traffic in adipocytes, but on the other hand the
VAMP8-dependent GLUT4 trafficking step in this tissue appears to be
the endocytosis event [47]. Yet given the fact that VAMPs play different
trafficking roles in different tissues, the GLUT4 endocytosis regulation
by VAMP8 in adipose tissue is not incompatible with a possible role of
this VAMP member in GLUT4 traffic from the endosomes to the GSV in
the heart. Second, VAMP2 might fulfil this missing piece of traffic,
because this VAMP has also been reported to shuttle GLUT4 between
the endosomes and GSV in adipocytes [10]. In this scenario, VAMP2
would be also involved in contraction-stimulated GLUT4 translocation,
which was not observed. Hence, this scenario can be rejected. In con-
clusion, in cardiomyocytes the VAMP member involved in this step
awaits identification.
An additional issue of controversy is the role of the GSV in con-
traction-stimulated GLUT4 translocation. It has been generally accepted
that the main function of the GSV is to serve as storage compartment for
insulin-stimulated GLUT4 translocation [10,47,79], whereas the role of
the GSV in contraction-induced GLUT4 translocation is mostly not
mentioned. It is suggested (without evidence) that the endosomes are
important in contraction-induced GLUT4 translocation with the GSV
mediating insulin-stimulated GLUT4 translocation [80]. This scenario
predicts that during lipid-induced insulin resistance, acute contraction
stimulation is not able to induce GLUT4 translocation. Namely under
this condition, the endosomes are devoid of GLUT4 (see Section 2.6).
For gaining a better insight into this latter scenario, the key contraction-
induced signaling node AMPK should be taken into focus. As depicted
in Fig. 1, AMPK has been firmly implicated in contraction-induced
GLUT4 translocation, and has been well-studied in the context of
Fig. 3. Hypothetical roadmap of CD36 and GLUT4 traffic in the healthy heart. Both CD36 and GLUT4 are intracellularly stored within the (recycling) endosomes and
GLUT4 additionally in non-endosomal GLUT4 storage vesicles (GSV). VAMP 4 is specifically involved in CD36 translocation and translocates CD36 between the
mother endosomal compartment and a hypothetical endosomal CD36-specific intermediate compartment. A not yet identified VAMP (VAMP?, perhaps VAMP8)
translocates GLUT4 between the mother endosomal compartment and the GSV. VAMP2 and/or VAMP3 bring CD36 from the endosomal CD36-specific intermediate
compartment to the cell surface upon stimulation by insulin (including Akt2) and/or by contraction (including AMPK), respectively. Both VAMPs fulfil the same roles
in insulin/contraction-stimulated GLUT4 translocation from the GSV to the cell surface. VAMP2 mediates CD36 return into the mother/CD36-specific endosomes.
VAMP5 and VAMP7 mediate GLUT4 return to intracellular compartments. VAMP5 could be specific for internalization to GSV and VAMP7 for endosomal return, but
the specific functioning of these VAMPs could also be flipped. Luminal acidification (of endosomes) is indicated by a blue fill color.
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insulin resistant myocytes, in which it serves as target for improvement
of insulin-stimulated GLUT4 translocation. For this purpose, a great
number of compounds have been tested on their ability to activate
AMPK during long-term addition, including numerous compounds ex-
tracted from exotic plants (e.g., [81,82]). In contrast, the acute effect of
AMPK activators on GLUT4 translocation in insulin resistant cells has
been scarcely investigated. Yet, the few reports that investigated this
issue, show that short-term contraction and AMPK activation lead to
GLUT4 translocation in the insulin resistant setting (e.g., see [83,84]).
Further evidence for a role of the GSV in contraction-induced GLUT4
translocation is that TBC1D1, the RabGAP supposedly involved in
contraction-induced GLUT4 translocation, binds to IRAP in the GSV
[85]. Upon AMPK-mediated phosphorylation, TBC1D1 disattaches from
IRAP, thereby allowing GLUT4 translocation [85]. Yet another piece of
independent evidence comes from the observation that AMPK activa-
tion can lead to IRAP translocation [86]. Taken together, the available
evidence is in favor of a role of the GSV in contraction-induced GLUT4
translocation, which is mediated by VAMP3.
4.3. Integration of CD36 and GLUT4 traffic
Based on defining the roles of specific VAMP members in the dis-
tinct steps in CD36 and GLUT4 traffic in combination with the specific
characteristics of endosomal and non-endosomal storage compartments
(see Sections 4.1 and 4.2), a putative roadmap of CD36 and GLUT4
traffic in cardiomyocytes has been constructed, which is depicted in
Fig. 3. With this roadmap we attempt to create a new starting point for
discussion. It shows the effects of insulin and contraction on CD36 and
GLUT4 traffic (see Legend of Fig. 3). It also provides a plausible ex-
planation for the differential subcellular fates of CD36 and GLUT4 upon
pharmacologically-induced loss of endosomal acidification (via bafilo-
mycin-induced v-ATPase inhibition or via treatment with the H+-io-
nophore monensin). Dissipation of the endosomal pH gradient will
expel both CD36 and GLUT4 from the mother endosomal compartment.
CD36 then travels with the aid of VAMP4 to the endosomal inter-
mediary station, but cannot stay there since also this station is mal-
functioning, and therefore has to travel completely to the cell surface.
Perhaps VAMP2 and VAMP3 can substitute for each other to mediate
CD36 translocation upon loss of endosomal acidification. In parallel,
GLUT4 travels from the endosomes to the GSV, where it is well ac-
commodated since this compartment is not affected by the subcellular
pH gradient-lowering drugs. GLUT4 cannot travel further to the cell
surface because VAMP2 and VAMP3 are likely not activated under this
condition.
5. Application of the roadmap to explain altered CD36 and GLUT4
traffic in the heart during insulin resistance
A largely unresolved issue in the field of trafficking of CD36 and
GLUT4 is that in the healthy heart CD36 and GLUT4 appear to travel
simultaneously from intracellular compartments to the cell surface
upon physiological stimuli, such as insulin and increased contractile
activity, whereas at the onset of cardiac insulin resistance CD36 and
GLUT4 behave quite differently: CD36 is expelled to the cell surface and
GLUT4 is imprisoned intracellularly. How can the roadmap be exploited
to explain these aberrant trafficking processes in the heart during excess
lipid availability? This is summarized in Fig. 4A. As described in Section
1.3, the initial trigger for the aberrant CD36 and GLUT4 trafficking
fates is the persistent increase in plasma lipid concentrations due to
chronic overconsumption. This results in increased fatty acid (palmi-
tate) uptake into the cardiomyocytes via the resident CD36 pool at the
cell surface. As described in Section 2.4, the rise in intracellular pal-
mitate is subsequently sensed by v-ATPase, which then disassembles,
rendering the endosomes unable to serve as storage compartment for
CD36 and GLUT4 (Section 2, introductory paragraph), enforcing CD36
to translocate to the cell surface (Section 1.3) and GLUT4 to the GSV
(Section 2.6). Then, the increased sarcolemmal CD36 together with the
increased plasma lipid concentrations will install the feed-forward loop
of CD36-mediated CD36 translocation (Section 2.5) and further massive
lipid accumulation culminating into impairment of insulin signaling
(Section 1.3). One of the targets of insulin signaling is VAMP2 (see
Section 3.1), and the insulin resistant state would imply a lack of ac-
tivation of VAMP2, rendering this VAMP unable to mediate GLUT4
translocation to the cell surface. On the other hand, contraction-in-
duced GLUT4 translocation is not affected by lipid-induced insulin re-
sistance [22,30] indicating that VAMP3 is normally operative. To-
gether, this implies that during insulin resistance GLUT4 is imprisoned
within the GSV. Namely, the VAMP2 inhibition precludes GLUT4
translocation to the cell surface, and the endosomal de-acidification
precludes a return of GLUT4 from the GSV to the endosomes. Only
VAMP3 activation would be able to release GLUT4 from the GSV during
lipid overload. When assumed that expression levels of VAMP2 exceed
those of VAMP3, it would be expected that VAMP3 would not be able to
fully compensate for the loss of activation of VAMP2 in bringing GLUT4
to the cell surface. Additionally, VAMP2 would fail to mediate CD36
translocation during insulin resistance, but since the total CD36 pool is
already at the cell surface, VAMP2 dysfunction is of no consequence for
CD36 traffic. In conclusion, the roadmap may help understand the
differential trafficking behavior of CD36 and GLUT4 in the heart upon
the onset of lipid overload (Fig. 4A).
The roadmap may also be employed to design novel strategies to
normalize CD36 and GLUT4 traffic via targeting of v-ATPase and
VAMPs. One such strategy may involve overexpression of VAMP3 in
cardiomyocytes, as already has been investigated [67]. In cardiomyo-
cytes cultured under low lipid conditions, overexpression of VAMP3 did
not influence insulin-stimulated glucose uptake, reconfirming that
VAMP3 is not involved in insulin-stimulated glucose uptake in the
healthy heart. In contrast, VAMP3 overexpression rescued insulin-sti-
mulated GLUT4 translocation in cardiomyocytes cultured in high lipid-
containing media. Additionally, cell surface accumulation of CD36 was
prevented. Moreover, the build-up of excess myocellular lipid depots
and the contractile dysfunction were no longer observed. Remarkably,
insulin signaling was not restored within the period of measurement.
From this, we deduced the following sequence of events: VAMP3
overexpression allows the formation of extra GLUT4 vesicles from the
GSV, which are made available for the insulin signaling pathway during
the condition of insulin resistance (Fig. 4B). These extra GLUT4 vesicles
would then be sufficient to compensate for the partial inhibition of
insulin signaling and subsequent insulin-induced VAMP2 activation.
These beneficial effects of VAMP3 overexpression could be mi-
micked by a possible drug-induced activation of VAMP3. Since VAMP3
is activated through the contraction pathway directly by PKD1 (see
Section 3.2), a specific activation of PKD1 by pharmacological ap-
proaches would also normalize insulin-stimulated GLUT4 translocation
during lipid overload. As proof of principle, adenoviral PKD1 over-
expression led to preservation of insulin-stimulated GLUT4 transloca-
tion in lipid-overloaded cardiomyocytes [87] presumably via the PKD1
– VAMP3 axis [67]. Upon restoration of GLUT4 translocation, also
glucose uptake is re-installed and intracellular glucose levels normal-
ized. Since v-ATPase is regulated by glucose (Section 2.2), the nor-
malization of glucose levels will lead to re-assembly of v-ATPase and re-
acidification of the endosomes. This will pull CD36 back from the cell
surface leading to restoration of low basal fatty acid uptake rates and
breakdown of excess lipid storage (Fig. 4B). We also expect the insulin
signaling pathway to recover as one of the later stage alterations, but
apparently the lowering of the intracellular lipid levels is already suf-
ficient to rescue the contractile dysfunction as seen under lipid over-
load.
Finally, also other VAMP members involved in GLUT4 and CD36
traffic could be targeted to protect against lipid-induced cardiac failure.
The roadmap predicts that downregulation of VAMP4 and upregulation
of VAMP5 and VAMP7 might be beneficial. Downregulation of VAMP4
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limits CD36 translocation by any stimulus and would lead to decreased
cardiac fatty acid uptake. Upregulation of VAMP5 and VAMP7 would
lead to decreased GLUT4 retention and stimulate glucose uptake. All
these manipulations would aim to restore the substrate balance in the
lipid-overloaded diabetic heart [88]. This could be tested in future re-
search.
For the roadmap, we focussed on v-ATPase and VAMPs to regulate
CD36 and GLUT4 traffic. Clearly, these proteins are not the only ones to
regulate trafficking. Other proteins with an important contribution to
the specificity of trafficking of cargo proteins in general and to that of
GLUT4 more specifically, are the Rab proteins, their adaptors and their
inhibitors (the RabGAPs). For instance, Rab10 is involved in endosomal
recycling of GLUT4 whereas Rab14 mediates the GSV recycling of
GLUT4 [89]. Rab11 was the first Rab member established to be in-
volved in CD36 traffic, and associated with CD36 internalization [90].
Finally, in analogy to the VAMP members similarly involved in CD36
and GLUT4 traffic, being VAMP2 (insulin-induced translocation) and
VAMP3 (contraction-induced translocation), a Rab member has been
identified, being Rab8a to be similarly involved in CD36 and GLUT4
traffic (i.e., insulin-induced translocation) [91]. In conclusion, the
roadmap could be expanded by including Rabs and possibly other
regulatory trafficking proteins to offer a more in-depth view of reg-
ulation of CD36 and GLUT4 traffic. Then new strategies can be designed
to alter cardiac substrate preference. This could be of major importance
not only in lipid-induced cardiomyopathy, but also in other cardiac
diseases with metabolic fingerprints.
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